Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03115567 · ClinicalTrials.gov registry record · Phase 2
A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03115567 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 14 participants.
The verdict
NCT03115567, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This randomized, controlled, phase II clinical study is designed to assess the efficacy of preemptive treatment with topical steroids in preventing the papulopustular eruption induced by epidermal growth factor receptor inhibitor (EGFRI) treatment in cancer patients. Participants will be followed up for 6 weeks of twice daily application of triamcinolone cream to the face, chest, and back.
Interventions
- DRUG Triamcinolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03115567
The ClinicalTrials.gov registry entry for NCT03115567 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triamcinolone is the first listed.
NCT03115567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03115567 about?
NCT03115567 is a clinical study titled "A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption". This randomized, controlled, phase II clinical study is designed to assess the efficacy of preemptive treatment with topical steroids in preventing the papulopustular eruption induced by epidermal growth factor receptor inhibitor (EGFRI) treatment in cancer patients. Participants will be followed up...
What is the current status of trial NCT03115567?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2017-02-16. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT03115567?
The interventions under investigation include: Triamcinolone (DRUG).
Who is sponsoring clinical trial NCT03115567?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.